It is possible that the association between dopamine agonists and cholinesterase inhibitors could have masked measurable effects on memory tasks.37 On the other hand, the medial temporal lobe is a site of complex pathological mechanisms linking neurodegeneration with neuroinflammation38 that likely begin long before cognitive decline appears, making the contribution of dopaminergic neurotransmission negligible in patients with moderate Alzheimer disease. The gene discussed is BCHE; the disease is Alzheimer disease.